JSC NextGen

NextGen is a Russian biotechnology company specializing in the development of gene therapy drugs and regenerative medicine solutions. As a key subsidiary of Artgen Biopharma (formerly Human Stem Cells Institute), the company achieved a global milestone by developing and launching Neovasculgen, the world's first plasmid-based gene therapy approved for the treatment of Peripheral Artery Disease and Critical Limb Ischemia. NextGen's core expertise lies in its proprietary plasmid DNA platform, which is designed to stimulate therapeutic angiogenesis in patients with chronic ischemia. The company's lead product has been commercially available in Russia since 2011 and is included in the state's list of vital medicines. NextGen continues to explore new indications for its gene therapy candidates while maintaining a focus on the Russian and CIS pharmaceutical markets.